You are here: Industry Insights > Remdesivir

News List

Beximco Pharma launches first generic remdesivir for Covid-19 pharmaceutical-technology
May 26, 2020
Bangladesh-based generic pharmaceuticals manufacturer Beximco Pharmaceuticals has launched the first generic version of antiviral drug remdesivir, originally developed by Gilead Sciences.
Cipla to explore remdesivir multi-drug combination for Covid-19 pharmaceutical-technology
May 20, 2020
India-based Cipla has plans to explore the use of multi-drug combination, including Gilead Sciences’ investigational antiviral drug remdesivir, for the treatment of Covid-19 coronavirus infection.
COVID-19 clinical trials exhibit encouraging results: GlobalData expresspharma
May 18, 2020
Four multinational clinical trials that are planning to enrol the most subjects are investigating remdesivir, sarilumab and bevacizumab.
Mylan partners with Gilead to manufacture remdesivir, potential COVID-19 treatment europeanpharmaceuticalreview
May 15, 2020
According to a new agreement between Mylan and Gilead, the former has the rights to manufacture and distribute remdesivir in 127 countries, a drug being tested to combat COVID-19.
Health groups ask India to rescind Gilead’s patents for COVID-19 drug remdesivir expresspharma
May 15, 2020
Gilead’s three patents in India for remdesivir stem from 2009 when the drug was in development to treat Ebola.
Mylan to Supply Remdesivir for Potential Treatment of COVID-19 americanpharmaceuticalreview
May 14, 2020
Mylan announced a global collaboration with Gilead Sciences to expand access to the investigational antiviral remdesivir for the potential treatment of COVID-19.
Gilead signs Voluntary Licensing Agreements with Cipla, Hetero Labs, Jubilant Lifesciences, Mylan fo expresspharma
May 14, 2020
Under the licensing agreements, the companies have a right to receive a technology transfer of the Gilead manufacturing process for remdesivir to enable them to scale up production more quickly.
Cipla enters into a licensing agreement With Gilead to expand access to COVID-19 treatment expresspharma
May 13, 2020
As part of the agreement, Cipla will be permitted to manufacture the API and Finished product, and market it in 127 countries including India and South Africa under Cipla’s own brand name.
Jubilant Life Sciences and Gilead sign agreement for Remdesivir expresspharma
May 13, 2020
Jubilant will now have the right to receive a technology transfer of the Gilead manufacturing process to scale up production to enable expedited access of the medicine to COVID-19 patients upon approvals by regulatory authorities in respective countries.
Gilead, Mylan Ink Global Remdesivir License Agreement contractpharma
May 13, 2020
To supply Remdesivir for potential COVID-19 treatment in 127 low- and middle-income countries.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page